跳至主要内容
临床试验/ISRCTN37913976
ISRCTN37913976已完成未知

A feasibility study to inform the design of a randomised controlled trial to identify the most clinically and cost effective length of anticoagulation with low molecular weight heparin In the treatment of Cancer Associated Thrombosis

Cardiff University (UK)0 个研究点目标入组 200 人开始时间: 2012年10月31日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
200

研究概览

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Receiving low-molecular-weight heparin (LMWH) for treatment of Cancer Associated Thrombosis (CAT) for five months
  • 2. Locally advanced or metastatic cancer
  • 3. Able to self-administer LMWH, or have LMWH administered by a carer
  • 4. Able to give informed consent
  • 5. Age =18 years

排除标准

  • 1. Receiving drug other than LMWH for CAT
  • 2. Contraindication to anticoagulation
  • 2.1. Known allergies to LMWHs, heparin, sulfites or benzyl alcohol
  • 2.2. Active major bleeding
  • 2.3. History of heparin-induced thrombocytopenia
  • 3. Confirmed recurrent VTE whilst receiving anticoagulation
  • 4. Female patients who are pregnant

研究者

发起方
Cardiff University (UK)

相似试验